238 related articles for article (PubMed ID: 29323731)
1. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Ng Kee Kwong F; Laggner U; McKinney O; Croud J; Rice A; Nicholson AG
Histopathology; 2018 May; 72(6):1024-1032. PubMed ID: 29323731
[TBL] [Abstract][Full Text] [Related]
2. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
Vallonthaiel AG; Malik PS; Singh V; Kumar V; Kumar S; Sharma MC; Mathur S; Arava S; Guleria R; Jain D
Ann Diagn Pathol; 2017 Dec; 31():56-61. PubMed ID: 29146060
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.
Farkašová A; Tancoš V; Kviatkovská Z; Huťka Z; Mičák J; Scheerová K; Szépe P; Plank L
Cesk Patol; 2018; 54(3):137-142. PubMed ID: 30445818
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
Miyazawa T; Marushima H; Saji H; Kojima K; Hoshikawa M; Takagi M; Nakamura H
Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):1-9. PubMed ID: 30282880
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores.
Gagné A; Enlow W; Pigeon MA; Orain M; Turcotte S; Bossé Y; Joubert P
Am J Surg Pathol; 2018 May; 42(5):687-694. PubMed ID: 29309297
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype.
Naso JR; Wang G; Pender A; Wong SK; Zhu J; Ho C; Ionescu DN; Zhou C
Histopathology; 2020 Feb; 76(3):394-403. PubMed ID: 31454429
[TBL] [Abstract][Full Text] [Related]
9. High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
Eur J Cancer; 2016 Jun; 60():125-35. PubMed ID: 27107327
[TBL] [Abstract][Full Text] [Related]
10. Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma.
Tancoš V; Grendár M; Farkašová A; Huťka Z; Mičák J; Kviatkovská Z; Hardman TC; Hardy GAD; Plank L
Pathology; 2020 Aug; 52(5):538-545. PubMed ID: 32586689
[TBL] [Abstract][Full Text] [Related]
11. Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
Yoon N; Kim J; Maeng LS; Ahn JH; Park ES
Anticancer Res; 2018 Oct; 38(10):6003-6008. PubMed ID: 30275232
[TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.
Ye L; Leslie C; Jacques A; Mesbah Ardakani N; Amanuel B; Millward M
Mod Pathol; 2019 Apr; 32(4):524-531. PubMed ID: 30401947
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma.
Liu Y; Dong Z; Jiang T; Hou L; Wu F; Gao G; He Y; Zhao J; Li X; Zhao C; Zhang W; Tian Q; Pan Y; Wang Y; Yang S; Wu C; Ren S; Zhou C; Zhang J; Hirsch FR
Clin Lung Cancer; 2018 Jul; 19(4):e421-e430. PubMed ID: 29609906
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.
Vigliar E; Malapelle U; Iaccarino A; Acanfora G; Pisapia P; Clery E; De Luca C; Bellevicine C; Troncone G
J Clin Pathol; 2019 Jun; 72(6):412-417. PubMed ID: 30846480
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
Li C; Huang C; Mok TS; Zhuang W; Xu H; Miao Q; Fan X; Zhu W; Huang Y; Lin X; Jiang K; Hu D; Chen X; Huang P; Lin G
J Thorac Oncol; 2017 Oct; 12(10):1536-1543. PubMed ID: 28751245
[TBL] [Abstract][Full Text] [Related]
17. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
[TBL] [Abstract][Full Text] [Related]
18. Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status.
Holmes M; Mahar A; Lum T; Kao S; Cooper WA
J Clin Pathol; 2021 Feb; 74(2):123-128. PubMed ID: 32576631
[TBL] [Abstract][Full Text] [Related]
19. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
[TBL] [Abstract][Full Text] [Related]
20. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
Yang CY; Lin MW; Chang YL; Wu CT
Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]